从美国联邦医疗保险视角对转移性前列腺癌中额外局部前列腺放疗的成本效果分析
该研究基于STAMPEDE试验数据,采用分区生存模型,从美国医疗体系视角评估在标准治疗基础上增加前列腺放疗对转移性前列腺癌不同亚组的成本效果。结果显示,仅非区域淋巴结转移患者和骨转移灶不超过三个的患者中,额外放疗分别获得0.92和3.83个增量质量调整生命年,增量成本效果比分别为28,452美元/质量调整生命年和40,032美元/质量调整生命年,在10万美元/质量调整生命年的支付意愿阈值下具有成本效果。
要点
- 仅非区域淋巴结转移患者中,额外放疗获得0.92增量质量调整生命年,增量成本效果比为28,452美元/质量调整生命年。
- 骨转移灶不超过三个的患者中,额外放疗获得3.83增量质量调整生命年,增量成本效果比为40,032美元/质量调整生命年。
- 概率敏感性分析显示,在10万美元/质量调整生命年阈值下,两个亚组中额外放疗作为成本效果策略的概率均超过96%。
核心结论
- 在仅非区域淋巴结转移和骨转移灶不超过三个的患者中,与标准治疗相比,额外前列腺放疗具有成本效果。
研究设计与样本
- 采用分区生存模型,使用STAMPEDE试验的临床数据,从美国医疗体系视角进行分析,成本和不良事件费用来自联邦医疗保险覆盖范围,健康状态效用值来自公共数据库和文献。
主要发现
- 仅非区域淋巴结转移患者中,额外放疗获得0.92增量质量调整生命年,成本增加26,098美元,增量成本效果比为28,452美元/质量调整生命年。
- 骨转移灶不超过三个的患者中,额外放疗获得3.83增量质量调整生命年,成本增加153,490美元,增量成本效果比为40,032美元/质量调整生命年。
- 敏感性分析显示模型对各种参数具有稳健性。
- 在支付意愿阈值为100,000美元/质量调整生命年的概率敏感性分析中,使用10,000次迭代的蒙特卡洛模拟,两个亚组中额外放疗作为成本效果策略的概率均超过96%。
关键数值与推荐
- 支付意愿阈值设定为每质量调整生命年100,000美元。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic prostate cancer remains a therapeutic challenge. Based on data of the STAMPEDE trial, patients with a low metastatic burden showed prolonged failure-free and overall survival when treated with prostate radio therapy (RT) in addition to standard of care (SOC). The objective of this study was to determine the cost-effectiveness of additional prostate RT compared to SOC alone for following subgroups: non-regional lymph node (NRLN) metastases, up to three bone metastases and four or more bone metastases. METHODS: A partitioned survival model was implemented with clinical data from STAMPEDE trial. Analyses were performed from a United States healthcare system perspective. Costs for treatment and adverse events were derived from Medicare coverage. Utilities for health states were derived from public databases and literature. Outcome measurements included incremental costs, effectiveness, and cost-effectiveness ratio. The willingness-to-pay threshold was set to USD 100,000 per quality-adjusted life year (QALY). RESULTS: Additional RT led to 0.92 incremental QALYs with increased costs of USD 26,098 with an incremental cost-effectiveness ratio (ICER) of USD 28,452/QALY for patients with only NRLN metastases and 3.83 incremental QALYs with increased costs of USD 153,490 with an ICER of USD 40,032/QALY for patients with up to three bone metastases. Sensitivity analysis showed robustness of the model regarding various parameters. In probabilistic sensitivity analysis using Monte Carlo simulation with 10,000 iterations, additional RT was found as the cost-effective strategy in over 96% for both subgroups iterations at a willingness-to-pay threshold of USD 100,000/QALYs. CONCLUSIONS: Additional RT is cost-effective in patients with only NRLN metastases and up to three metastases compared to SOC.
引用
- Kramer KKM, Schmidt-Hegemann NS, Westhofen T, et al. Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective. Radiat Oncol. 2024. PMID: 39574140. doi:10.1186/s13014-024-02544-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。